BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Studies have indicated that BCR (breakpoint cluster region)-ABL kinase inhibitors used to treat chronic myeloid leukemia, such as dasatinib, nilotinib, and imatinib, have significant inhibitory effects on DDR2 kinase.88